Cargando…

Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010

RATIONALE: COPD has attracted widespread attention worldwide. The prevalence of COPD in Taiwan has been reported, but little is known about trends in health care resource utilization and pharmacologic management in COPD treatment. OBJECTIVE: The objective of this article was to study trends in healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Ying-Huang, Yang, Tsung-Ming, Lin, Chieh-Mo, Huang, Shu-yi, Wen, Yu-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627724/
https://www.ncbi.nlm.nih.gov/pubmed/29026296
http://dx.doi.org/10.2147/COPD.S147968
_version_ 1783268756643905536
author Tsai, Ying-Huang
Yang, Tsung-Ming
Lin, Chieh-Mo
Huang, Shu-yi
Wen, Yu-Wen
author_facet Tsai, Ying-Huang
Yang, Tsung-Ming
Lin, Chieh-Mo
Huang, Shu-yi
Wen, Yu-Wen
author_sort Tsai, Ying-Huang
collection PubMed
description RATIONALE: COPD has attracted widespread attention worldwide. The prevalence of COPD in Taiwan has been reported, but little is known about trends in health care resource utilization and pharmacologic management in COPD treatment. OBJECTIVE: The objective of this article was to study trends in health care resource utilization, pharmacologic management, and medical costs of COPD treatment in Taiwan. MATERIALS AND METHODS: Reimbursement claims in the Taiwan National Health Insurance System from 2004 to 2010 were collected. The disease burden of COPD, including health care resource utilization and medical costs, was evaluated. RESULTS: The pharmacy cost of COPD increased from 2004 to 2010 due to the increased utilization of long-acting muscarinic antagonist (LAMA) and fixed-dose combination of long-acting β2-agonist and inhaled corticosteroid (LABA/ICS), whereas the cost of all other COPD-related medications decreased. The average outpatient department (OPD) cost per patient increased 29.3% from 1,070 USD in 2004 to 1,383 USD in 2010. The highest average total medical cost per patient was 3,434 USD in 2005, and it decreased 12.4% to 3,008 USD in 2010. There was no significant difference in the average number of OPD visits and emergency department visits per patient. The highest average number of hospital admissions was 0.81 in 2005, and it decreased to 0.65 in 2010. The average number of intensive care unit (ICU) admissions decreased from 0.52 in 2005 to 0.31 in 2010. CONCLUSION: From 2004 to 2010, the average total medical cost per patient of COPD was slightly decreased because of the decreased average number of hospital admissions and ICU admissions. The costs of both LAMA and LABA/ICS increased, while the cost for all other COPD-related medications decreased. These findings suggest that the increased utilization of LAMA and LABA/ICS may have contributed to the decreased average number of hospital admissions and ICU admissions in COPD patients from 2004 to 2010.
format Online
Article
Text
id pubmed-5627724
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56277242017-10-12 Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010 Tsai, Ying-Huang Yang, Tsung-Ming Lin, Chieh-Mo Huang, Shu-yi Wen, Yu-Wen Int J Chron Obstruct Pulmon Dis Original Research RATIONALE: COPD has attracted widespread attention worldwide. The prevalence of COPD in Taiwan has been reported, but little is known about trends in health care resource utilization and pharmacologic management in COPD treatment. OBJECTIVE: The objective of this article was to study trends in health care resource utilization, pharmacologic management, and medical costs of COPD treatment in Taiwan. MATERIALS AND METHODS: Reimbursement claims in the Taiwan National Health Insurance System from 2004 to 2010 were collected. The disease burden of COPD, including health care resource utilization and medical costs, was evaluated. RESULTS: The pharmacy cost of COPD increased from 2004 to 2010 due to the increased utilization of long-acting muscarinic antagonist (LAMA) and fixed-dose combination of long-acting β2-agonist and inhaled corticosteroid (LABA/ICS), whereas the cost of all other COPD-related medications decreased. The average outpatient department (OPD) cost per patient increased 29.3% from 1,070 USD in 2004 to 1,383 USD in 2010. The highest average total medical cost per patient was 3,434 USD in 2005, and it decreased 12.4% to 3,008 USD in 2010. There was no significant difference in the average number of OPD visits and emergency department visits per patient. The highest average number of hospital admissions was 0.81 in 2005, and it decreased to 0.65 in 2010. The average number of intensive care unit (ICU) admissions decreased from 0.52 in 2005 to 0.31 in 2010. CONCLUSION: From 2004 to 2010, the average total medical cost per patient of COPD was slightly decreased because of the decreased average number of hospital admissions and ICU admissions. The costs of both LAMA and LABA/ICS increased, while the cost for all other COPD-related medications decreased. These findings suggest that the increased utilization of LAMA and LABA/ICS may have contributed to the decreased average number of hospital admissions and ICU admissions in COPD patients from 2004 to 2010. Dove Medical Press 2017-09-28 /pmc/articles/PMC5627724/ /pubmed/29026296 http://dx.doi.org/10.2147/COPD.S147968 Text en © 2017 Tsai et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Tsai, Ying-Huang
Yang, Tsung-Ming
Lin, Chieh-Mo
Huang, Shu-yi
Wen, Yu-Wen
Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010
title Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010
title_full Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010
title_fullStr Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010
title_full_unstemmed Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010
title_short Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010
title_sort trends in health care resource utilization and pharmacological management of copd in taiwan from 2004 to 2010
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627724/
https://www.ncbi.nlm.nih.gov/pubmed/29026296
http://dx.doi.org/10.2147/COPD.S147968
work_keys_str_mv AT tsaiyinghuang trendsinhealthcareresourceutilizationandpharmacologicalmanagementofcopdintaiwanfrom2004to2010
AT yangtsungming trendsinhealthcareresourceutilizationandpharmacologicalmanagementofcopdintaiwanfrom2004to2010
AT linchiehmo trendsinhealthcareresourceutilizationandpharmacologicalmanagementofcopdintaiwanfrom2004to2010
AT huangshuyi trendsinhealthcareresourceutilizationandpharmacologicalmanagementofcopdintaiwanfrom2004to2010
AT wenyuwen trendsinhealthcareresourceutilizationandpharmacologicalmanagementofcopdintaiwanfrom2004to2010